BioSpace News Archive

Glaukos Corporation announced that its management is scheduled to participate in the Citi Healthcare Conference on Wednesday, March 1, 2023, at 1:15 p.m. ET in New York City.

Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the independent Data Monitoring Committee (DMC) reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML) and recommended the study should continue to the originally planned final overall survival event trigger.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced interim data from the Phase 2 study evaluating the combination of VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, and BRII-835 (VIR-2218), an HBV-targeting siRNA candidate, in chronically infected HBV patients.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 (NCT03581786).

Nexcella, Inc. (“Nexcella”, “Company”) today announced that it has entered into a manufacturing agreement with a well-known United States Good Manufacturing Practice (GMP) cell therapy manufacturer that will supply a US Phase 1b/2 clinical trial of NXC-201 in relapsed/refractory multiple myeloma and AL amyloidosis.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA) today announced top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware.

Galera Therapeutics, Inc. announced that it has agreed to sell 14,320,000 shares of common stock and warrants to purchase up to 14,320,000 shares of common stock in a registered direct offering at a combined offering price of $2.095 per share and accompanying warrant.

Lightbeam Health Solutions, the leader in population health enablement solutions and services, today announces that the United States Patent and Trademark Office (USPTO) has issued U.S. patent number 11,494,724 B2 covering Lightbeam’s population health technology for Outcomes and Performance Monitoring.

Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”) today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2022 on Thursday, February 23, 2023 after U.S. markets close.